<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
         xmlns="http://purl.org/rss/1.0/"
         xmlns:admin="http://webns.net/mvcb/"
         xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
         xmlns:dc="http://purl.org/dc/elements/1.1/"
         xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
  <channel rdf:about="https://hstalks.com/rss/by-category/758/">
    <title>Immunology</title>
    <link>https://hstalks.com/category/758/immunology/?biosci</link>
    <description>New and updated series &amp; talks on Immunology from HSTalks&#x27; Biomedical &amp; Life Sciences Collection.</description>
    <admin:generatorAgent rdf:resource="http://www.hstalks.com/" />
    <admin:errorReportsTo rdf:resource="mailto:info@hstalks.com" />
    <sy:updatePeriod>daily</sy:updatePeriod>
    <sy:updateFrequency>1</sy:updateFrequency>
    <sy:updateBase>2006-01-01T12:00+00:00</sy:updateBase>
    <dc:publisher>Henry Stewart Talks</dc:publisher>
    <dc:language>en</dc:language>
    <dc:rights>© Copyright Henry Stewart Talks Ltd.</dc:rights>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
    <prism:copyright>© Copyright Henry Stewart Talks Ltd.</prism:copyright>
    <items>
      <rdf:Seq>
      <rdf:li resource="https://hstalks.com/t/24084/the-environment-scleroderma/?biosci" />
      <rdf:li resource="https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23521/mucosal-vaccine-adjuvants/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22102/walking-on-water-load-bearing-joint-perfusion-and-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27038/chronic-inflammation-mechanisms/?biosci" />
      <rdf:li resource="https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci" />
      <rdf:li resource="https://hstalks.com/t/20353/the-evolving-landscape-of-sepsis-from-empiricism-t/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23686/blood-cleansing-as-immunotherapy-testing-a-novel-c/?biosci" />
      <rdf:li resource="https://hstalks.com/t/21475/psoriasis-diagnosis-overview/?biosci" />
      
      </rdf:Seq>
    </items>
  </channel>

  <item rdf:about="https://hstalks.com/t/24084/the-environment-scleroderma/?biosci">
    <title>The environment &amp; scleroderma [12 mins] </title>
    <link>https://hstalks.com/t/24084/the-environment-scleroderma/?biosci</link>
    <description>Systemic sclerosis (scleroderma) - Pathogenesis of systemic sclerosis (SSc) - Gene-susceptibility and gene-environment interaction in SSc - Environmental risk factors - Epigenetic impact of toxins - Infectious triggers - Microbiome alteration in SSc - Medications associated with scleroderma-like skin changes or scleroderma</description>
    <dc:title>The environment &amp; scleroderma</dc:title>
    
    <dc:creator>Dr. Zsuzsanna McMahan</dc:creator>
    
    <dc:subject>Systemic sclerosis (scleroderma), Pathogenesis of systemic sclerosis (SSc), Gene-susceptibility and gene-environment interaction in SSc, Environmental risk factors, Epigenetic impact of toxins, Infectious triggers, Microbiome alteration in SSc, Medications associated with scleroderma-like skin changes or scleroderma</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci">
    <title>Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer [19 mins] </title>
    <link>https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci</link>
    <description>Endometrial cancer immunotherapy - Immune biomarkers - Nivolumab - Cabozantinib - Tumour microenvironment - Macrophages - Personalised cancer treatment - Immunotherapy resistance</description>
    <dc:title>Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer</dc:title>
    
    <dc:creator>Prof. Sacha Gnjatic</dc:creator>
    
    <dc:subject>Endometrial cancer immunotherapy, Immune biomarkers, Nivolumab, Cabozantinib, Tumour microenvironment, Macrophages, Personalised cancer treatment, Immunotherapy resistance</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23521/mucosal-vaccine-adjuvants/?biosci">
    <title>Mucosal vaccine adjuvants [37 mins] </title>
    <link>https://hstalks.com/t/23521/mucosal-vaccine-adjuvants/?biosci</link>
    <description>Vaccines and immunization programmes - Adjuvants potency, selection and development - Immune cells, PRR and ligands - Key factors of mucosal immunity - Mucosal immunity advantages and limitations - Mucosal vaccine delivery system - Mucosal adjuvants and mucosal immune response</description>
    <dc:title>Mucosal vaccine adjuvants</dc:title>
    
    <dc:creator>Dr. Sivakumar S. Moni</dc:creator>
    
    <dc:subject>Vaccines and immunization programmes, Adjuvants potency, selection and development, Immune cells, PRR and ligands, Key factors of mucosal immunity, Mucosal immunity advantages and limitations, Mucosal vaccine delivery system, Mucosal adjuvants and mucosal immune response</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci">
    <title>Targeting the intestinal barrier in GVHD and checkpoint colitis [20 mins] </title>
    <link>https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci</link>
    <description>Acute graft-versus-host disease (aGVHD): Clinical presentation - Intestinal inflammation during aGVHD - Treatment of aGVHD - Kinase targets in GVHD - REACH2 trial - Colitis and other irAEs after immune checkpoint blockade - ECP is an effective therapy for inflammatory diseases - Arginase-1 is central in ECP-induced immunomodulation</description>
    <dc:title>Targeting the intestinal barrier in GVHD and checkpoint colitis</dc:title>
    
    <dc:creator>Prof. Robert Zeiser</dc:creator>
    
    <dc:subject>Acute graft-versus-host disease (aGVHD): Clinical presentation, Intestinal inflammation during aGVHD, Treatment of aGVHD, Kinase targets in GVHD, REACH2 trial, Colitis and other irAEs after immune checkpoint blockade, ECP is an effective therapy for inflammatory diseases, Arginase-1 is central in ECP-induced immunomodulation</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22102/walking-on-water-load-bearing-joint-perfusion-and-/?biosci">
    <title>Walking on water: load bearing, joint perfusion and osteoarthritis [24 mins] </title>
    <link>https://hstalks.com/t/22102/walking-on-water-load-bearing-joint-perfusion-and-/?biosci</link>
    <description>Joints - IOP measurement - Factor affecting IOP measurements - Significance of IOPv - IOPa - Load - Vascular markings in MRI scans - Correlation between vascular marks and Kellgren - Lawrence grade - Bone histology - Choke valve</description>
    <dc:title>Walking on water: load bearing, joint perfusion and osteoarthritis</dc:title>
    
    <dc:creator>Dr. Michael Beverly</dc:creator>
    
    <dc:subject>Joints, IOP measurement, Factor affecting IOP measurements, Significance of IOPv, IOPa, Load, Vascular markings in MRI scans, Correlation between vascular marks and Kellgren, Lawrence grade, Bone histology, Choke valve</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27038/chronic-inflammation-mechanisms/?biosci">
    <title>Chronic inflammation mechanisms [4 mins] </title>
    <link>https://hstalks.com/t/27038/chronic-inflammation-mechanisms/?biosci</link>
    <description>Chronic inflammation mechanisms - Acute vs chronic inflammation - Cellular and molecular pathways - Key cytokines and immune cells - Chronic inflammation in diseases - Innate and adaptive immunity roles - Therapeutic approaches and immune modulation</description>
    <dc:title>Chronic inflammation mechanisms</dc:title>
    
    
    <dc:subject>Chronic inflammation mechanisms, Acute vs chronic inflammation, Cellular and molecular pathways, Key cytokines and immune cells, Chronic inflammation in diseases, Innate and adaptive immunity roles, Therapeutic approaches and immune modulation</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci">
    <title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials [37 mins] </title>
    <link>https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci</link>
    <description>Ongoing clinical trials for bladder cancer - Enfortumab-vedotin &amp; pembrolizumab as first-line therapy - Disitamab vedotin &amp; toripalimab (PD1 inhibitor) for the treatment of metastatic UC - Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions - Remission with cisplatin-based NAC - mRNA-4157 (V940): customizable individualized mRNA immunotherapy - Adjuvant chemotherapy - Neoadjuvant Chemo-IO combination therapy</description>
    <dc:title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials</dc:title>
    
    <dc:creator>Prof. Guru P. Sonpavde</dc:creator>
    
    <dc:subject>Ongoing clinical trials for bladder cancer, Enfortumab-vedotin &amp; pembrolizumab as first-line therapy, Disitamab vedotin &amp; toripalimab (PD1 inhibitor) for the treatment of metastatic UC, Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions, Remission with cisplatin-based NAC, mRNA-4157 (V940): customizable individualized mRNA immunotherapy, Adjuvant chemotherapy, Neoadjuvant Chemo-IO combination therapy</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/20353/the-evolving-landscape-of-sepsis-from-empiricism-t/?biosci">
    <title>The evolving landscape of sepsis: from empiricism to precision medicine [59 mins] </title>
    <link>https://hstalks.com/t/20353/the-evolving-landscape-of-sepsis-from-empiricism-t/?biosci</link>
    <description></description>
    <dc:title>The evolving landscape of sepsis: from empiricism to precision medicine</dc:title>
    
    <dc:creator>Prof. Ignacio Martin-Loeches</dc:creator>
    
    <dc:subject></dc:subject>
    <dc:date>2026-09-21</dc:date>
    <prism:publicationDate>2026-09-21</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23686/blood-cleansing-as-immunotherapy-testing-a-novel-c/?biosci">
    <title>Blood cleansing as immunotherapy: testing a novel cancer vaccine strategy [18 mins] </title>
    <link>https://hstalks.com/t/23686/blood-cleansing-as-immunotherapy-testing-a-novel-c/?biosci</link>
    <description>Cancer vaccines - Cancer immunotherapy - Ovarian cancer - Tumour antigens - Whole-cell vaccines - T-cell activation - Tumour microenvironment - Clinical development of immunotherapies</description>
    <dc:title>Blood cleansing as immunotherapy: testing a novel cancer vaccine strategy</dc:title>
    
    <dc:creator>Prof. Raymond Goodrich</dc:creator>
    
    <dc:subject>Cancer vaccines, Cancer immunotherapy, Ovarian cancer, Tumour antigens, Whole-cell vaccines, T-cell activation, Tumour microenvironment, Clinical development of immunotherapies</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/21475/psoriasis-diagnosis-overview/?biosci">
    <title>Psoriasis: diagnosis &amp; overview [38 mins] </title>
    <link>https://hstalks.com/t/21475/psoriasis-diagnosis-overview/?biosci</link>
    <description>Clinical identification of psoriasis - Pathogenesis - Classification of psoriasis - Psoriatic arthritis - Enthesitis - Comorbidities in psoriatic disease - Malignancy and psoriasis - Quality of life in psoriasis</description>
    <dc:title>Psoriasis: diagnosis &amp; overview</dc:title>
    
    <dc:creator>Dr. Tina Bhutani</dc:creator>
    
    <dc:subject>Clinical identification of psoriasis, Pathogenesis, Classification of psoriasis, Psoriatic arthritis, Enthesitis, Comorbidities in psoriatic disease, Malignancy and psoriasis, Quality of life in psoriasis</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

</rdf:RDF>
